Electronic Acknowledgement Receipt				
EFS ID:	1125711			
Application Number:	09121798			
Confirmation Number:	3701			
Title of Invention:	METHODS FOR PURIFYING NUCLEIC ACIDS			
First Named Inventor:	ROBERT BRIDENBAUGH			
Correspondence Address:	Marilyn M. Iluston WONG CABELLO, LUTSCH, RUTHERFORD & BRUCCULERI, LLP 20333 SH 249 Suite 600 Houston TX 77070 US 415 576 0300			
Filer:	Marilyn Huston			
Filer Authorized By:				
Attorney Docket Number:	018484-00120			
Receipt Date:	24-JUL-2006			
Filing Date:	23-JUL-1998			
Time Stamp:	21:34:03			
Application Type:	Utility			
International Application Number:				
Dovmont information:				

Payment information:

Submitted with Payment	yes
Payment was successfully received in RAM	\$225

RAM confirmation Number	689
Deposit Account	501922
The Director of the USPTO is hereby authorized to ch	harge indicated fees and credit any overpayment as follows:

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows.

Charge any Additional Fees required under 37 C.F.R. Section 1.16 and 1.17

File Listing:

Number	Document Description	File Name	File Size(Bytes)	Multi Part	Pages
1	Applicant Arguments/Remarks Made in an Amendment	Response_OA_2_23_06.pdf	147697	no	11
Warnings:					
Information	:				
2	Information Disclosure Statement (IDS) Filed	US_IDS_FormSB_08.pdf	662171	no	4
Warnings:					
Information	:				
	lable within the Image File Wrapper (IFW Foreign Patent Documents or Non Paten				
3	NPL Documents	Gerba_1985.pdf	910077	no	3
	NPL Documents	Gerba_1985.pdf	910077	no	3
Warnings:		Gerba_1985.pdf	910077	no	3
		Gerba_1985.pdf	910077	no	3
Warnings:		Gerba_1985.pdf biopharm_catalog_redacted_ USPTO.pdf	910077	no	9
Warnings: Information	:	biopharm_catalog_redacted_			
Warnings: Information	: NPL Documents	biopharm_catalog_redacted_			
Warnings: Information 4 Warnings:	: NPL Documents	biopharm_catalog_redacted_			
Warnings: Information 4 Warnings: Information	: NPL Documents	biopharm_catalog_redacted_ USPTO.pdf	3446641	no	9
Warnings: Information 4 Warnings: Information 5	: NPL Documents : Fee Worksheet (PTO-875)	biopharm_catalog_redacted_ USPTO.pdf	3446641	no	9

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.